PENTAX-MEDICAL
HOYA (TOKYO:7741) today announced that it has signed an agreement to acquire a majority shareholding in Wassenburg Group, an Automated Endoscope Reprocessing (AER) market leader in the Netherlands. The planned closing date is November 1, 2013.
This strategic acquisition enables HOYA through its division PENTAX Medical to give its global customers complete access to a superior and wider portfolio in the field of flexible endoscopy from Endoscopes to AERs. The same synergies will also be driven by Wassenburg as the respective installed base customers and new customers will have a wider portfolio to benefit from.
Flexible endoscopy is approximately a $2.5B market globally and growing at an average 8 - 10% annually. The AER market is approximately a $1.0B market globally and growing at 10% - 12% annually. With this joint venture HOYA will now have access to a $3.5B market globally and also heralds a shift from a capital equipment company to enter the segment of consumables too.
The growth of the endoscopy market is driven by changing demographics, new minimally invasive procedures, new diagnostic technologies and new therapeutic endoscopic procedures which are increasing the number of endoscopy procedures. At the same time every endoscope after clinical use must be decontaminated with the same degree of rigor following every endoscopic procedure to prevent cross-contamination of patients. This underscores the importance of endoscope reprocessing and following disinfection guidelines to attain best practice and improve patient care. The trend in the market is the shift from manual to standardized automated reprocessing of endoscopes and presents a great growth opportunity.
This joint venture is about product synergies, channel synergies and geographic expansion. Wassenburg Medical Devices has direct operations and significant presence in western European countries with their leading edge AERs. Through this strategic alliance with HOYA they will now have a platform for entry in the world’s largest Endoscopy market, the USA and also into the emerging markets of Asia Pacific, Latin America, Eastern Europe and Middle East Africa. This strategic deal not only widens the portfolio for the HOYA customers but also offers a platform for growth into new markets and new segments.
“This is a great match for us and a significant step forward for our global endoscopy strategy,” said Jayant Saha, Senior Vice President, Global BD, PENTAX Medical, HOYA Group. “Wassenburg is a fantastic company. Their management have done a great job building the company and we look forward to taking advantage of the strengths of our combined companies as we expand the product offerings globally into existing and new markets.”
The transaction will involve the purchase of more than 50 percent of the shares of Wassenburg Group. The share acquisition is the latest step in HOYA’s plan to gain share in all markets globally and the widening of the product portfolio positions HOYA to capture market share everywhere.
"Instilling greater clinical confidence by delivering high performance, reliability and value to our customers is at the core of everything we do," said Ganesh Ramaswamy, Global President, PENTAX Medical. "Now PENTAX Medical along with Wassenburg look forward to offering seamless product offerings in the field of Endoscopy to our customers."
“We have built Wassenburg into the number one AER company in the Netherlands.” said Arno Wassenburg, MD of Wassenburg Medical Devices BV. “This is a wonderful next step for our business, our customers and shareholders. Our customers will gain tremendous value from the ability to access a total endoscopy portfolio that this deal ensures.”
"Wassenburg has found the best possible partner in HOYA" said Ronald Wassenburg, MD of Wassenburg Medical Devices BV. “It’s been a privilege to help build Wassenburg, now we will grow our global presence and market share even more by leveraging the global strength of HOYA."
"Any time two leadership companies like HOYA and Wassenburg pair together to offer a technologically superior and wider portfolio, the customer benefits," said Girts Cimermans, COO, HOYA Lifecare. "Our strategic joint venture will bring new synergies in the market and benefit both companies’ leadership products."
About HOYA
HOYA is a global med-tech company established in Tokyo, Japan, and the leading supplier of innovative and indispensable high-tech products based on its advanced optics technologies.
HOYA is active in two main business segments: The Life Care providing indispensable products to improve people´s QOL such as eyeglasses, medical endoscopes and intraocular lenses, and the Information Technology providing key components and imaging products for the semiconductor devices, PCs, and mobile devices. Hoya employs over 30,000 people in more than 30 countries.
ABOUT WASSENBURG MEDICAL DEVICES B.V.
Wassenburg Medical Devices B.V. is a leading international company based in the Netherlands and specializing in the development and manufacture of innovative high-level washer disinfectors and drying/conditioning cabinets for flexible endoscopes. The company was established in 1984 and has developed into a highly-qualified specialist in all aspects of automated endoscope reprocessing. With head offices and manufacturing premises in the Netherlands and Vietnam, offices in the United Kingdom, Ireland, Belgium and France, the full product range is distributed through an exclusive distribution network in Europe, the Middle East, Africa and the Asia Pacific region.
Contact:
Hoya Group
PENTAX Medical
Kaori Kawashima
Mobile phone:
+81-80-4794-5842
GM, Global Marketing Communication
kaori.kawashima@pentaxmedical.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
The Six Winning Projects of the 12th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 16:58:00 CEST | Press release
The winners of the 2024 IBSA Foundation Fellowships Call come from two US, two Swedish, one Italian and one British universities.This year’s edition set a new record: 259 projects submitted from 45 countries.The awards ceremony was held today in Milan; during the event, the 2025 call for applications was officially opened. Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the
Rigaku Completes New Building at Yamanashi Plant27.5.2025 16:00:00 CEST | Press release
Dramatic 2.7-fold increase in floor space to serve global demand Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum